/Jiu'an Medical: Special report on the storage, management and use of raised funds in 2025

NEWS

Jiu'an Medical: Special report on the storage, management and use of raised funds in 2025

Shenzhen Stock Exchange

2026/04/29

Securities code: 002432 Securities abbreviation: Jiuan Medical Announcement number: 2026-017

Tianjin Jiuan Medical Electronics Co., Ltd.

Special report on the storage, management and use of raised funds in 2025. The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete.

There are no false records, misleading statements or material omissions.

1. Basic situation of raised funds

Tianjin Jiu'an Medical Electronics Co., Ltd. (hereinafter referred to as the "Company") has been approved by the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") "Reply on the Approval of the Non-public Issuance of Stocks by Tianjin Jiu'an Medical Electronics Co., Ltd." (CSRC License [2020] No. 3324). The company's non-public issuance of RMB ordinary shares (A shares) in 2020 is 45,797,101 shares, with a par value of RMB 1.00 per share. The issue price was RMB 6.90 per share, and the total amount of funds raised was RMB 315,999,996.90. After deducting the issuance-related expenses of RMB 6,630,702.76, the actual net amount of funds raised was RMB 309,369,294.14. The above-mentioned receipt of funds raised has been verified by Dahua Accounting Firm (Special General Partnership) and issued the "Capital Verification Report on the Non-public Issuance of RMB Ordinary Shares (A Shares) of Tianjin Jiu'an Medical Electronics Co., Ltd." (Dahua Yanzi [2021] No. 000141).

As of December 31, 2025, the company's use and balance of raised funds are as follows:

Item Amount (RMB)

Total funds raised 315,999,996.90

Less: issuance expenses 6,630,702.76

Actual net amount of funds raised 309,369,294.14

Less: Cumulative use of raised funds 251,666,377.69

Including: raised funds used this year 48,747,861.19

Add: interest income 25,165,255.29

Less: Handling fee expenses 8,866.27

Raised funds account balance 82,859,305.47

2. Storage and management of raised funds

(1) Management of raised funds

In order to strengthen and standardize the management of raised funds, improve the efficiency of fund use, and safeguard the legitimate interests of shareholders, the company has formulated a "Raised Funds Management System" in accordance with the provisions of the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations of Main Board Listed Companies", "Shenzhen Stock Exchange Stock Listing Rules" and other laws, regulations and normative documents. The company implements special account storage and special use management of raised funds in accordance with the requirements of the management system and combined with operational needs.

The company signed a "Tripartite Supervision Agreement on Raised Funds" with the sponsor institution Pacific Securities Co., Ltd. and the Industrial and Commercial Bank of China Tianjin Guoxin Binshuidao Branch in March 2021. The company signed a "Four-Party Supervision Agreement on Raised Funds" with its subsidiaries Coton (Tianjin) Electronic Medical Equipment Co., Ltd., Pacific Securities Co., Ltd. and Tianjin Huayuan Branch of Industrial Bank Co., Ltd. in June 2021. The company, its subsidiary Beijing Aihe Health Technology Services Co., Ltd., the Beijing Shangdi Branch of China Merchants Bank Co., Ltd., and the sponsoring institution Pacific Securities Co., Ltd. signed the "Four-Party Supervision Agreement on Raised Funds" in September 2022. The company signed a "Tripartite Supervision Agreement on Raised Funds" with the sponsor institution Pacific Securities Co., Ltd. and Shanghai Pudong Development Bank Tianjin Branch in April 2024. In April 2025, due to the company's new fund-raising project "Construction of the R&D Office Headquarters Building and Upgrading and Renovation of the Original Factory Area", after consensus among the three parties, the company continued to use the original fund-raising account, and added "Construction of the R&D Office Headquarters Building and Upgrading and Renovation of the Original Factory Area" to the fund-raising project in the original agreement, and re-signed a three-party supervision agreement for raised funds.

There are no major differences between the three-party supervision agreement (including the four-party supervision agreement) and the Shenzhen Stock Exchange's three-party supervision agreement template. They comply with relevant regulations. There are no problems with the performance of the three-party supervision agreement (including the four-party supervision agreement). As of the date of this report, the performance of the three-party supervision agreement (including the four-party supervision agreement) was normal.

(2) Storage status of raised funds in special accounts

As of December 31, 2025, the specific deposit status of the raised funds is as follows:

Amount unit: RMB

Bank name Account number Deposit amount Storage method

Industrial Bank Tianjin Huayuan Branch 441130100100520703 0.03 Current

Industrial and Commercial Bank of China Tianjin Binshuidao Branch 0302060619300091704 1,848.72 Current

Industrial and Commercial Bank of China Tianjin Binshui Road Branch 0302060614200004526 80,000,000.00 Regular

China Merchants Bank Beijing Shangdi Branch 110950235910302 32.80 Current

Shanghai Pudong Development Bank Tianjin Branch 77010078801700008031 2,857,423.92 Current

Total - 82,859,305.47 -

3. Actual use of funds raised this year

(1) Comparison table of usage of raised funds

The company will use 48.7479 million yuan of raised funds in 2025. As of December 31, 2025, the company has used a total of 251.6664 million yuan of raised funds. Please see Appendix 1 for a comparison table of the use of raised funds.

(2) Changes in implementation locations and implementation methods of investment projects with raised funds

Change of project implementation location

In 2025, the company's project implementation location has not changed. The changes in historical years before 2025 are as follows:

On April 29, 2022, the company held the 24th meeting of the fifth board of directors and reviewed and approved the "Proposal on Clarifying the Fund Usage Arrangements for the Fund Raised Investment Project "Joint Care Center Expansion and System R&D Upgrade Project": In order to smoothly carry out business, the use arrangements for care service projects are clarified as follows: Under the "Diabetes Care Service and Related Product Research and Development Project" The sub-project "Common Care Center Expansion and System R&D Upgrade Project" plans to use 209 million yuan of raised funds, of which 40 million yuan will be used directly by the company to develop care services and R&D investment in Tianjin; the company will set up a wholly-owned subsidiary in Beijing to use 169 million yuan to invest in care services and R&D investment in Beijing and other regions. As of the end of the reporting period, Beijing Aihe Health Technology Services Co., Ltd. has been established.

On April 28, 2023, the company held the third meeting of the sixth board of directors and the third meeting of the sixth board of supervisors, and reviewed and approved the "Proposal on Adjusting the Investment Amount of Some Raised Investment Projects and Adding Implementing Subjects". In order to improve the efficiency of the use of raised funds and ensure the smooth implementation of the raised fund investment project "Common Care Center Expansion and System R&D Upgrade Project", accelerate the promotion of projects in more cities In line with the city's plan to build a "common care" center and serve more diabetic patients, the company added Tianjin Aiheang Technology Development Co., Ltd. as the implementation entity of the "Common Care Center Expansion and System R&D Upgrade Project". The investment amount of each entity reviewed in the early stage was changed accordingly, and the raised funds were jointly used by the company, Beijing Aihe Health Technology Service Co., Ltd., and Tianjin Aihealth Technology Development Co., Ltd. As of December 31, 2025, Tianjin AiHealth Technology Development Co., Ltd. has not incurred any project expenditures on raised funds.

Changes in project implementation methods

The company held the 20th meeting of the sixth board of directors and the 15th meeting of the sixth board of supervisors on April 3, 2025. The company held the first extraordinary shareholders' meeting of 2025 on April 21, 2025, and reviewed and approved the "Proposal on the Extension, Closing and Use of Surplus Raised Funds for Investment Projects Partially Raised Funds". Because the "Continuous Blood Glucose Monitoring System (CGMS) R&D Project", a sub-project of the "Diabetes Care Services and Related Products R&D Project", continued to use savings from other projects to raise funds, and the market demand for test kits has increased significantly in the past few years, the company devoted its main energy and resources to the R&D, production and sales of the product. Employees worked together to fully support the test kit project, which resulted in the overall progress of the project slowing down. The company has adjusted the implementation period of the project and extended it from March 5, 2025 to March 31, 2027. For details, please refer to the "Announcement on the Delay, Closing and Use of Surplus Raised Funds for Investment Projects with Partial Raised Funds" disclosed by the company on April 4, 2025 (Announcement Number: 2025-018).

(3) Situations in which the benefits of investment projects with raised funds cannot be separately calculated

The Continuous Blood Glucose Monitoring System (CGMS) research and development project is a new product research and development project for the company. Due to the long time for research and development, testing and registration of medical device products, the benefits cannot be calculated separately. However, it can lay a solid foundation for the company to enrich blood glucose monitoring related products and improve blood sugar management solutions in the future, and have a positive impact on the company's performance, thereby indirectly improving the company's benefits.

The construction of the R&D office headquarters building and the upgrading and renovation of the original factory area are non-production projects. The projects do not directly generate profits and do not require separate financial evaluation. After the implementation of this project is completed, the benefits will mainly be reflected in the substantial improvement of the company's overall R&D strength and innovation capabilities, which will be conducive to upgrading the company's technology system and creating new profit growth points. The company has always attached great importance to research and development, and this project will help improve the company's research and development efficiency and thereby enhance its overall core competitiveness. In addition, the R&D office headquarters building can better achieve energy conservation, emission reduction, and green environmental protection, helping to improve energy efficiency and reduce energy consumption.

(4) Advance investment and replacement of raised funds in investment projects

Before the funds raised this time were actually in place, the company first invested 15.3779 million yuan of self-raised funds. This matter has been verified by Dahua Accounting Firm (Special General Partnership), and the "Authentication Report of Tianjin Jiu'an Medical Electronics Co., Ltd. Preliminarily Investing Raised Funds in Investment Projects with Self-raised Funds" (Dahua Hezi [2021] No. 006469). The 14th meeting of the fifth session of the Board of Directors of the company reviewed and approved the "Proposal on Substituting Raised Funds for Self-raised Funds Pre-invested in Fund-raising Projects and Issue Fees Paid". The actual replacement amount was 15.3779 million yuan, and the replacement work was completed in June 2021.

The company held the 27th meeting of the sixth board of directors and the 21st meeting of the sixth board of supervisors on October 13, 2025, and reviewed and approved the "Proposal on Using Own Funds to Pay the Funds Required for Raised Investment Projects and Replacement with Raised Funds in Equal Parts". It was agreed that the company would use its own funds to pay part of the funds for the raised investment projects during the implementation of the raised investment projects, and subsequently replace them with raised funds in equal amounts on a regular basis. For details, please refer to the "Announcement on Using Own Funds to Pay for Funds Required for Raised Investment Projects and Replacement with Raised Funds in Equal Balance" disclosed by the company on October 14, 2025 (Announcement Number: 2025-076).

(5) Temporarily supplementing working capital with idle raised funds

The Company does not use idle raised funds to temporarily replenish working capital.

(6) Cash management using idle raised funds

The company's 21st meeting of the sixth board of directors and the 16th meeting of the sixth board of supervisors held on April 21, 2025 respectively reviewed and approved the "Proposal on the Company's Use of Part of Idle Raised Funds for Cash Management", and agreed that the company would not affect the normal construction of investment projects with raised funds and the safety of raised funds. Use part of the temporarily idle raised funds with a total limit of no more than RMB 110 million for cash management, and authorize the company's management to make investment decisions and sign relevant contract documents. The relevant limit of this resolution will take effect from the expiration date of the limit reviewed and approved by the 11th meeting of the sixth session of the Board of Directors for a period of 12 months. Within the above usage period and quota range, the funds can be used on a rolling basis.

(7) Usage of surplus raised funds

The company held the 20th meeting of the sixth board of directors and the 15th meeting of the sixth board of supervisors on April 3, 2025. The company held the first extraordinary shareholders' meeting of 2025 on April 21, 2025, and reviewed and approved the "Proposal on the Extension, Closing and Use of Surplus Raised Funds for Investment Projects Partially Raised Funds". In view of the fact that the sub-project "Common Care Center Expansion and System R&D Upgrade Project" of the company's fund-raising project "Diabetes Care Services and Related Product R&D Project" has been completed, in order to improve the efficiency of the use of raised funds, the total savings from the raised investment project are RMB 11,476.34 Ten thousand yuan (including cash management income and interest, based on the actual amount in the special account on the day when the funds are transferred out), will be used respectively for the original sub-project "Continuous Blood Glucose Monitoring System (CGMS) R&D Project" of the "Diabetes Care Services and Related Product R&D Project" and the new project "R&D Office Headquarters Building Construction and Original Factory Area Upgrading Project". For details, please refer to the "Announcement on the Delay, Closing and Use of Surplus Raised Funds for Investment Projects Partially Raised Funds" disclosed by the company on April 4, 2025 (Announcement Number: 2025-018).

(8) Usage of excess raised funds

The company has no use of excess raised funds.

(9) Purpose and destination of unused raised funds

As of December 31, 2025, unused raised funds are deposited in current deposits, time deposits, etc. in special raised fund accounts. The company conducts cash management of idle raised funds within the approved quota in accordance with regulations.

(10) Other situations of use of raised funds

The company has no other use of raised funds.

4. Change the use of funds raised for investment projects

On April 28, 2023, the company held the third meeting of the sixth board of directors and the third meeting of the sixth board of supervisors, and reviewed and approved the "Proposal on Adjusting the Investment Amount of Some Raised Investment Projects and Adding Implementing Subjects". In order to improve the efficiency of the use of raised funds, ensure the long-term development of the main business and safeguard the interests of all shareholders, the company will use the remaining raised funds of the "New Generation Intelligent Thermometer Project" and the "Intelligent UV Air Disinfection Machine R&D Project" to 885.85 The change of 10,000 yuan will be used to invest in the "Continuous Blood Glucose Monitoring System (CGMS) R&D Project." Please see Appendix 2 for details of the change in investment projects with raised funds.

5. Problems in the use and disclosure of raised funds

There is no situation where the information related to the use of raised funds disclosed by the company is not disclosed in a timely, true, accurate and complete manner.
The company used a total of 60 million yuan of temporarily idle raised funds to purchase cash management products from March 29, 2022 to April 28, 2022, and the company failed to perform review procedures and information disclosure obligations in a timely manner. The above-mentioned principal and income have all been recovered on schedule, and no losses have been caused to the company and shareholders. The company and relevant personnel will carefully learn lessons, continue to strengthen their study of relevant laws, regulations and normative documents, further improve the company's awareness of standardized operations and the quality of information disclosure, and prevent such incidents from happening again. Except for the above, there are no violations in the storage, use and management of the company's raised funds.

Attached table: 1. Comparison table of usage of raised funds;

Change the list of investment projects with raised funds.

Board of Directors of Tianjin Jiuan Medical Electronics Co., Ltd.

April 28, 2026

Schedule 1:

Comparison table of usage of raised funds

Prepared by: Tianjin Jiuan Medical Electronics Co., Ltd. 2025 Unit: RMB 10,000

Total raised funds 31,600.00 Total raised funds invested during the year 4,874.79 Total raised funds changed in use during the reporting period 0.00

Cumulative total amount of raised funds that have been changed in use 885.85 Total amount of raised funds that have been invested 25,166.64 Cumulative proportion of total raised funds that have been changed in use

2.80%

Yes No The raised funds have been changed. After adjustment, the investment in this year has been completed. As of the end of the period, the investment projects as of the end of the period have reached the expected implementation. Yes No, the project feasibility has been reached. Commitment investment projects and super-raised funds investment direction change projects (including committed investment total amount. Cumulative investment progress (%) (3) must determine the benefits that can be used. Estimated benefits Whether re-occurrence

Partial change) Total amount (1) Amount (2) = (2)/(1) Status date Big change

Commitment to investment projects

Diabetes care services and related product research and development projects Yes 27,300.00 24,565.90 4,622.81 22,151.63 90.17% 2027/3/31 Not applicable Not applicable No Intelligent factory renovation project No 1,600.00 1,600.00 0.00 1,611.95 100.75% 2023/3/5 Not applicable Not applicable No New generation intelligent thermometer project Yes 1,500.00 1,151.08 0.00 1,151.08 100.00% -- Not applicable Not applicable Yes Intelligent UV air disinfection machine research and development project Yes 1,200.00 0.00 0.00 0.00 -- -- Not applicable Not applicable It is the construction of the R&D office headquarters building and the upgrade of the original factory area

No 0.00 6,123.64 251.98 251.98 4.11% 2027/3/31 Not applicable Not applicable No renovation project

Total -- 31,600.00 33,440.62 4,874.79 25,166.64 75.26% -- -- -- --

Investment direction of super-raised funds Not applicable

Failure to achieve planned progress or expected benefits and

Not applicable

Reason (divided into specific projects)

Explanation of major changes in project feasibility. The fundraising projects "New Generation Intelligent Thermometer Project" and "Intelligent UV Air Disinfection Machine R&D Project" were developed based on a specific background. The current market environment has

If changes occur, it is expected that the market demand for the project's products will drop significantly, and there will be greater uncertainty in subsequent capital investment and the achievement of R&D results. Amount, purpose and progress of use of excess raised funds Not applicable

Changes in the implementation location of investment projects with raised funds The 24th meeting of the company's fifth board of directors reviewed and approved the "Proposal on Clarifying the Fund Usage Arrangements for the Fund Raising Project "Joint Care Center Expansion and System R&D Upgrade Project": In order to smoothly carry out business, the use arrangements for care service projects are clarified as follows: the sub-project "Joint Care" under the "Diabetes Care Service and Related Product R&D Project" "Care Center Expansion and System R&D Upgrade Project", which plans to use 209 million yuan of raised funds, of which 40 million yuan will be used directly by the company to develop care services and R&D investment in Tianjin; the company will set up a wholly-owned subsidiary in Beijing and use 169 million yuan to invest in care services and R&D investment in Beijing and other regions. As of the end of the reporting period, Beijing Aihe Health Technology Services Co., Ltd. has been established.

Adjustments to the implementation methods of investment projects with raised funds The company held the 20th meeting of the sixth board of directors and the 15th meeting of the sixth board of supervisors on April 3, 2025, and held the first extraordinary shareholders' meeting of 2025 on April 21, 2025, which reviewed and approved the "Proposal on the Extension, Closing and Use of Surplus Raised Funds for Investment Projects with Partial Raised Funds". Because the "Continuous Blood Glucose Monitoring System (CGMS)" R&D project, a sub-project of the "Diabetes Care Services and Related Product R&D Project", continued to use funds raised from other projects, and the market demand for test kits increased significantly in the past few years, the company devoted its main energy and resources to the R&D, production and sales of the product. Employees worked together to fully support the test kit project, which resulted in the overall progress of the project slowing down. The company adjusted the implementation period of the project and extended it from March 5, 2025 to 2027. March 31, 2025. For details, please refer to the "Announcement on the Delay, Closing and Use of Surplus Raised Funds for Investment Projects" disclosed by the company on April 4, 2025 (Announcement Number: 2025-018).

Preliminary investment and replacement of raised funds in investment projects. Before the raised funds were actually received, the company first invested RMB 15.3779 million in self-raised funds. This matter has been verified by Dahua Accounting Firm (Special General Partnership), and the "Authentication Report on Tianjin Jiu'an Medical Electronics Co., Ltd.'s pre-investment of raised funds in investment projects with self-raised funds" (Dahua Hezi [2021] No. 006469). The 14th meeting of the fifth session of the Board of Directors of the company reviewed and approved the "Proposal on Substituting Raised Funds for Self-raised Funds Pre-invested in Fund-raising Projects and Issue Fees Paid". The actual replacement amount was 15.3779 million yuan, and the replacement work was completed in June 2021.

The company held the 27th meeting of the sixth board of directors and the 21st meeting of the sixth board of supervisors on October 13, 2025, and reviewed and approved the "Proposal on Using Own Funds to Pay the Funds Required for Raised Investment Projects and Replacement with Raised Funds in Equal Parts", agreeing that the company will use its own funds to pay part of the funds for the raised investment projects during the implementation of the raised investment projects, and then regularly use raised funds to replace them with equal amounts. For details, please refer to the "Announcement on Using Own Funds to Pay for the Funds Required for Raised Investment Projects and Replacement with Raised Funds in Equal Parts" disclosed by the company on October 14, 2025 (Announcement Number: 2025-076).

Use idle raised funds to temporarily supplement working capital

Not applicable

situation

Use of idle raised funds for cash management The 21st meeting of the sixth board of directors and the 16th meeting of the sixth board of supervisors held by the company on April 21, 2025 respectively reviewed and approved the "Proposal on the Company's Use of Part of Idle Raised Funds for Cash Management", and agreed that the total amount used by the company shall not exceed RMB 11,000 without affecting the normal construction of investment projects with raised funds and the safety of raised funds. Ten thousand yuan of partially temporarily idle raised funds will be used for cash management, and the company's management will be authorized to make investment decisions and sign relevant contract documents. The relevant quota for this resolution will take effect from the expiration date of the quota reviewed and approved by the eleventh meeting of the sixth session of the Board of Directors for a period of 12 months. Within the above usage period and quota range, the funds can be used on a rolling basis.

The amount of surplus raised funds arising from project implementation and the company held the 20th meeting of the sixth board of directors and the 15th meeting of the sixth board of supervisors on April 3, 2025, and convened the first extraordinary shareholders' meeting of 2025 on April 21, 2025, and reviewed and approved the "Proposal on the Extension, Closing and Use of Surplus Raised Funds for Investment Projects with Partial Raised Funds". In view of the fact that the sub-project "Common Care Center Expansion and System R&D Upgrade Project" of the company's fund-raising project "Diabetes Care Services and Related Product Research and Development Project" has been completed, in order to improve the efficiency of the use of raised funds, the remaining funds from the raised investment project totaled RMB 11,476.34 Ten thousand yuan (including cash management income and interest, based on the actual amount in the special account on the day when the funds are transferred out), will be used respectively for the original sub-project "Continuous Blood Glucose Monitoring System (CGMS) R&D Project" of the "Diabetes Care Services and Related Product R&D Project" and the new project "R&D Office Headquarters Building Construction and Original Factory Area Upgrading Project". For details, please refer to the "Announcement on the Delay, Closing of Partially Raised Funds for Investment Projects and the Use of Surplus Raised Funds" disclosed by the company on April 4, 2025 (Announcement Number: 2025-018). Purpose and destination of unused raised funds Unused raised funds are deposited in current deposits, time deposits, etc. in special accounts for raised funds. The company conducts cash management of idle raised funds within the approved quota in accordance with regulations.

Problems in the use and disclosure of raised funds or

During this reporting period, there were no problems or other situations in the use and disclosure of raised funds.

Other situations

Note 1: The total amount of raised funds changed in use during the reporting period and the cumulative total amount of raised funds changed in use during the reporting period are calculated based on the amount after deducting relevant issuance expenses.

2: The amount of raised funds to be invested in the above table is higher than the net amount of raised funds, which is due to including interest during the storage period of raised funds, financial management income and deduction of handling fees, etc. If there is new interest, financial management income and other income in the subsequent account, all of it will be used for "holding"

Continue the Blood Glucose Monitoring System (CGMS) R&D Project”.

Schedule 2

Changes in the status of investment projects with raised funds

Unit: 10,000 yuan

The changed project corresponds to the original promised project The changed project is planned to be implemented this year Actual as of the end of the period The investment as of the end of the period The project has reached the schedule The changed project

Whether the actual performance this year has reached

Input raised funds Actual investment Cumulative investment amount (%) (3) = (2) usable status date Whether feasibility has been determined

Current benefits Expected benefits

Total (1) Amount (2) / (1) Period Significant changes in diabetes care services and

Related product research and development projects

Diabetes Care Services and Smart UV Air Disinfection

24,565.90 4,622.81 22,151.63 90.17 2027-3-31 Not applicable Not applicable No

Related product R&D projects Machine R&D projects

A new generation of smart thermometer

Project

Total - 24,565.90 4,622.81 22,151.63 90.17 - - - -

On April 28, 2023, the company held the third meeting of the sixth board of directors and an explanation of the reasons for the changes, decision-making procedures and information disclosure of the sixth supervisory board (by specific projects) At the third meeting of the Board of Directors, the "Proposal on Adjusting the Investment Amount of Some Raised Investment Projects and Adding Implementing Subjects" was reviewed and approved. The raised investment projects "New Generation Intelligent Thermometer Project" and "Intelligent UV Air Disinfection Machine R&D Project" were established and developed based on a specific background. The current market environment has changed. It is expected that the market demand for the project's products will decline significantly, and there is great uncertainty in subsequent capital investment and the achievement of R&D results. In order to improve the efficiency of the use of raised funds, ensure the long-term development of the main business and safeguard the interests of all shareholders, the company changed the remaining raised funds of 8.8585 million yuan from the "New Generation Intelligent Thermometer Project" and "Intelligent UV Air Disinfection Machine R&D Project" to invest in the "Continuous Blood Glucose Monitoring System (CGMS) R&D Project." For details, please refer to the "Announcement on Adjusting the Investment Amount of Some Fund-raising Projects and Adding Implementing Subjects" disclosed by the company on April 29, 2023 (Announcement Number: 2023-018). Situations and reasons for failure to achieve planned progress or expected benefits (divided into specific projects)

Not applicable

Description of significant changes in project feasibility after change

Not applicable